Last 12 months
Inside the activity.
2 purchase rows · 116 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 15 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 29 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 31 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 11 |
| Jul 2026 | 2 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 15, 2019 Filed Jan 18, 2019 00:19 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionRestricted Stock Units · Derivative | 20,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000016 · edgar.xml · derivative · entry 3 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,100 Underlying: Common Stock · 20,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F4 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. F4 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:19 UTC |
PARSHALL B LYNNEDirector
|
Tax withholdingCommon Stock | 6,159 | $58.26 | $358,823.34 |
DisclosureSEC source: 0000874015-19-000016 · edgar.xml · nonDerivative · entry 2 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,677 F2 · kind: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. F2 · shares: Shares withheld to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 00:19 UTC |
PARSHALL B LYNNEDirector
|
Exercise / conversionCommon Stock | 20,656 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-19-000016 · edgar.xml · nonDerivative · entry 1 PARSHALL B LYNNE · CIK 0001073385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. F1 · shares: Acquired pursuant to vesting and release of shares pursuant to Restricted Stock Unit awards. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,000 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · derivative · entry 8 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,875 Underlying: Common Stock · 4,000 shares Expires 2021-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionEmpoyee Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · derivative · entry 7 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 4,000 | $54.80 | $219,200.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · nonDerivative · entry 5 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,584 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 4,000 | $39.87 | $159,480.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · nonDerivative · entry 4 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,584 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
SaleCommon Stock | 400 | $54.80 | $21,920.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · nonDerivative · entry 3 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,584 F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. Read SEC document |
| January 03, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
Exercise / conversionCommon Stock | 400 | $10.82 | $4,328.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · nonDerivative · entry 2 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. F3 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 08/29/18. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:44 UTC |
HOUGEN ELIZABETH LSVP Finance & CFO
|
GrantEmployee Stock Option (right to buy) · Derivative | 49,800 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000010 · edgar.xml · derivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 49,800 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
GrantEmployee Stock Option (right to buy) · Derivative | 49,800 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · derivative · entry 6 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,800 Underlying: Common Stock · 49,800 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:46 UTC |
McDevitt DamienChief Business Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 29,400 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000012 · edgar.xml · derivative · entry 1 McDevitt Damien · CIK 0001742277 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,400 Underlying: Common Stock · 29,400 shares Expires 2026-01-01 F1 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:42 UTC |
Monia Brett PChief Operating Officer
|
GrantEmployee Stock Option (right to buy) · Derivative | 102,900 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,900 Underlying: Common Stock · 102,900 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:42 UTC |
Monia Brett PChief Operating Officer
|
SaleCommon Stock | 214 | $53.50 | $11,449.00 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,837 F3 · kind: The Sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. F3 · shares: The Sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on 07/01/2014. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:34 UTC |
Geary Richard SSVP, Development
|
GrantEmployee Stock Option (right to buy) · Derivative | 57,900 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000006 · edgar.xml · derivative · entry 2 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,900 Underlying: Common Stock · 57,900 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:32 UTC |
BENNETT C FRANKSVP, Antisense Research
|
GrantEmployee Stock Option (right to buy) · Derivative | 46,800 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000004 · edgar.xml · derivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,800 Underlying: Common Stock · 46,800 shares Expires 2026-01-01 F2 · derivative.exercise_date: Grant of 01/02/2019 to reporting person of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:29 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000002 · edgar.xml · derivative · entry 2 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By wife Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2026-01-01 F1 · derivative.exercise_date: Grant of 01/02/2019 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 00:29 UTC |
CROOKE STANLEY TDirector · Chairman and CEO
|
GrantEmployee Stock Option (right to buy) · Derivative | 143,400 | $0.00 Strike: $53.77 | $0.00 |
DisclosureSEC source: 0000874015-19-000002 · edgar.xml · derivative · entry 1 CROOKE STANLEY T · CIK 0000897667 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,400 Underlying: Common Stock · 143,400 shares Expires 2026-01-01 F1 · derivative.exercise_date: Grant of 01/02/2019 to reporting person or reporting person's wife (as indicated) of stock options under the Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan. 25% of the shares subject to the option vest and become exercisable on 01/02/2020. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments over the next 3 years. Following this transaction, the option was exercisable as to 0 on 01/02/2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:44 UTC |
HOUGEN ELIZABETH LSVP Finance & CFO
|
OtherCommon Stock | 127 | $36.45 | $4,628.90 |
DisclosureSEC source: 0000874015-19-000010 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,901 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:50 UTC |
O'NEIL PATRICK R.SVP Legal & General Counsel
|
OtherCommon Stock | 66 | $36.45 | $2,405.57 |
DisclosureSEC source: 0000874015-19-000014 · edgar.xml · nonDerivative · entry 1 O'NEIL PATRICK R. · CIK 0001564926 · SVP Legal & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,584 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:42 UTC |
Monia Brett PChief Operating Officer
|
OtherCommon Stock | 210 | $36.45 | $7,654.08 |
DisclosureSEC source: 0000874015-19-000009 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,051 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:34 UTC |
Geary Richard SSVP, Development
|
OtherCommon Stock | 407 | $36.45 | $14,834.34 |
DisclosureSEC source: 0000874015-19-000006 · edgar.xml · nonDerivative · entry 1 Geary Richard S · CIK 0001442730 · SVP, Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,264 F1 · kind: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 00:32 UTC |
BENNETT C FRANKSVP, Antisense Research
|
OtherCommon Stock | 128 | $36.45 | $4,665.34 |
DisclosureSEC source: 0000874015-19-000004 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,524 F1 · kind: Reporting of shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. F1 · shares: Reporting of shares acquired under the Ionis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2019. These shares may not be sold until July 2, 2019. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,063 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · derivative · entry 6 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,063 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 2,063 | $52.05 | $107,379.15 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 4 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 19, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 2,063 | $7.25 | $14,956.75 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 3 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · derivative · entry 5 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,063 Underlying: Common Stock · 2,000 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
SaleCommon Stock | 2,000 | $52.00 | $104,000.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 2 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,774 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| December 18, 2018 Filed Dec 20, 2018 22:55 UTC |
HOUGEN ELIZABETH LSVP, Finance & CFO
|
Exercise / conversionCommon Stock | 2,000 | $7.25 | $14,500.00 |
DisclosureSEC source: 0000874015-18-000132 · edgar.xml · nonDerivative · entry 1 HOUGEN ELIZABETH L · CIK 0001074773 · SVP, Finance & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 11/07/2018. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · derivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC |
Monia Brett PChief Operating Officer
|
SaleCommon Stock | 34,000 | $55.00 | $1,870,057.80 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F2 · price: The price reported in Column 4 is a weighted average price. These share were sold in multiple transactions at prices ranging from $55.00 to $55.08, inclusiveThe reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 23, 2018 Filed Nov 27, 2018 01:01 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionCommon Stock | 34,000 | $14.69 | $499,460.00 |
DisclosureSEC source: 0000874015-18-000130 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 05/11/2018. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 23:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000124 · edgar.xml · derivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,013 Underlying: Common Stock · 12,500 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 23:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 12,500 | $49.54 | $619,245.00 |
DisclosureSEC source: 0000874015-18-000124 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,396 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.35 to $49.75, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Read SEC document |
| November 01, 2018 Filed Nov 1, 2018 23:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionCommon Stock | 12,500 | $14.69 | $183,625.00 |
DisclosureSEC source: 0000874015-18-000124 · edgar.xml · nonDerivative · entry 1 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 00:55 UTC |
Reikes Peter NDirector
|
GrantRestricted Stock Units · Derivative | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000121 · edgar.xml · derivative · entry 1 Reikes Peter N · CIK 0001753652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. F2 · derivative.expiration_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 00:51 UTC |
Hayden Michael RDirector
|
GrantRestricted Stock Units · Derivative | 7,110 | $0.00 | $0.00 |
DisclosureSEC source: 0000874015-18-000119 · edgar.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110 Underlying: Common Stock · 7,110 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. F2 · derivative.exercise_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. F2 · derivative.expiration_date: Grant of October 15, 2018 to reporting person of Restricted Stock Unit Award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. Restricted Stock Units vest in four equal annual installments, the first installment vesting on October 15, 2019. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. The RSU shall be fully vested on October 15, 2022. The RSU is vested as to 0 shares on October 15, 2018. Read SEC document |
| September 23, 2018 Filed Sep 25, 2018 00:04 UTC |
Reikes Peter NDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $49.14 | $0.00 |
DisclosureSEC source: 0000874015-18-000113 · edgar.xml · derivative · entry 1 Reikes Peter N · CIK 0001753652 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-09-22 F1 · derivative.exercise_date: Grant of September 23, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 23, 2019. The option shall be fully vested and exercisable on September 23, 2022. The option is exercisable to 0 shares on September 23, 2018. F1 · derivative.expiration_date: Grant of September 23, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 23, 2019. The option shall be fully vested and exercisable on September 23, 2022. The option is exercisable to 0 shares on September 23, 2018. Read SEC document |
| September 20, 2018 Filed Sep 25, 2018 00:14 UTC |
Hayden Michael RDirector
|
GrantDirector Stock Option (right to buy) · Derivative | 32,000 | $0.00 Strike: $50.80 | $0.00 |
DisclosureSEC source: 0000874015-18-000115 · edgar.xml · derivative · entry 1 Hayden Michael R · CIK 0001352908 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2028-09-19 F1 · derivative.exercise_date: Grant of September 20, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 20, 2019. The option shall be fully vested and exercisable on September 20, 2022. The option is exercisable to 0 shares on September 20, 2018. F1 · derivative.expiration_date: Grant of September 20, 2018 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on September 20, 2019. The option shall be fully vested and exercisable on September 20, 2022. The option is exercisable to 0 shares on September 20, 2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · derivative · entry 6 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2018-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 8,993 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · derivative · entry 5 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,993 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
SaleCommon Stock | 7,500 | $54.00 | $405,000.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 4 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionCommon Stock | 7,500 | $7.21 | $54,075.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 3 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,341 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
SaleCommon Stock | 8,993 | $54.00 | $485,622.00 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 2 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,841 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 27, 2018 Filed Aug 29, 2018 20:49 UTC |
Monia Brett PChief Operating Officer
|
Exercise / conversionCommon Stock | 8,993 | $7.25 | $65,199.25 |
DisclosureSEC source: 0000874015-18-000109 · edgar.xml · nonDerivative · entry 1 Monia Brett P · CIK 0001537529 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 5/11/2018. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,487 | $0.00 Strike: $14.69 | $0.00 |
DisclosureSEC source: 0000874015-18-000107 · edgar.xml · derivative · entry 6 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,513 Underlying: Common Stock · 12,487 shares Expires 2020-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 13 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0000874015-18-000107 · edgar.xml · derivative · entry 5 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13 shares Expires 2019-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 12,487 | $45.00 | $561,915.00 |
DisclosureSEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 4 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,396 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
Exercise / conversionCommon Stock | 12,487 | $14.69 | $183,434.03 |
DisclosureSEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 3 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
| August 08, 2018 Filed Aug 9, 2018 22:34 UTC |
BENNETT C FRANKSVP, Antisense Research
|
SaleCommon Stock | 13 | $45.00 | $585.00 |
DisclosureSEC source: 0000874015-18-000107 · edgar.xml · nonDerivative · entry 2 BENNETT C FRANK · CIK 0001073387 · SVP, Antisense Research 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,396 F1 · kind: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. F1 · shares: Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 12/8/2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.